Abstract
Despite the progress in treatment protocols, gastric cancer remains a challenging disease. Systemic chemotherapy is of crucial importance for patients with metastatic or recurrent disease, and new developments in chemotherapy regimens have been seen in recent years. An oral 5-fluororacil (5-FU) agent, S-1, is emerging, with promising results. Various S-1 combination regimens, mostly with cisplatin, are being examined extensively, and the combination of S-1 with oxaliplatin is the focus of recent studies. In this study, phase I/II studies of combination chemotherapy with S-1 and platinum in patients with metastatic or recurrent gastric cancer were reviewed. We found that the combination of S-1 plus cisplatin was highly active against advanced gastric cancer, with a favorable toxicity profile. The response rates were 53%-74% in Japan, 47.6% in Korea, and 51% in the United States and Europe. There is no internationally accepted standard care for patients with advanced gastric cancer yet, but S-1 is likely to replace infusional 5-FU, and oxaliplatin may represent an alternative to cisplatin in the near future. More innovative therapies, particularly with molecular-targeted drugs, are needed to meet the needs of patients in the era of tailored medicine.
Article PDF
Similar content being viewed by others
References
Parkin MD, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.
Lee JY, Kim HY, Kim KH, Jang HD, Kim JB, Lee JH, et al. No changing trends in incidence of gastric cardia cancer in Korea. J Korean Med Sci 2003;18:53–57.
Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005;10(Suppl 3):49–58.
Wagner AD, Grothe W, Haerting J, Klebr G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903–2909.
Scartozzi M, Galizia E, Verdecchia L, Berardi R, Antognoli S, Chiorrini S, et al. Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin Pharmacother 2007;8:797–808.
Ohtsu A. Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 2005;8:95–102.
Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003;6(Suppl 1):2–8.
Lee JL, Kang HJ, Kang YK, Ryu MH, Chang HM, Kim TW, et al. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother Pharmacol 2008;61:837–845.
Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191–197.
Nakata B, Mitachi Y, Tsuji A, Yamamitsu S, Hirata K, Shirasaka T, et al. Combination phase I trial of a novel oral fluorouracil derivative S-1 with low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902). Clin Cancer Res 2004;10:1664–1669.
Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, et al, Phase I study of S-1. Jpn J Cancer Chemother 1997;24:2253–2264.
Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207–2212.
Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassum) in advanced gastric cancer patients. Eur J Cancer 1998;34:715–720.
Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, et al. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer 2003;6(Suppl 1):45–49.
Tsujitani S, Fukuda K, Kaibara N. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer. Gastric Cancer 2003;6(Suppl 1):50–57.
Sato Y, Kondo H, Honda K, Takahari D, Sumiyoshi T, Tsuji Y, et al. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen. Int J Clin Oncol 2005;10:40–44.
Hyodo I, Nishina T, Moriwaki T, Endo S, Terao T, Hirao K, et al. A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting. Eur J Cancer 2003;39:2328–2333.
Kimura Y, Kikkawa N, Iijima S, Kato T, Naoi Y, Hayashi T, et al. A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer 2003;6(Suppl 1):34–39.
Nagashima F, Ohtsu A, Yoshida S, Ito K. Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 2005;8:6–11.
Chollet P, Schöffski P, Weigang-Köhler K, Schellens JH, Cure H, Pavlidis N, et al. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer: a trial performed by the EORTC early clinical studies group (ECSG). Eur J Cancer 2003;39:1264–1270.
Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 2005;23:6957–6965.
Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, et al. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 2002;8:2116–2122.
Zhu AX, Clark JW, Ryan DP, Meyechardt JA, Enzinger PC, Earle CC, et al. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol 2007;59:285–293.
Ajani JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB III, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:663–667.
Kelland L. The resurgence of platinum-based cancer chemotherapy. Cancer 2007;7:573–584.
Lourvet C, André JM, Tigaud E, Gamelin JY, Douillard, R, Brunet E, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;13:1469–1478.
De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005;92:1644–1649.
Cavanna L, Artioli F, Codignola C, Lazzaro A, Rizzi A, Gamboni A, et al. Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). Am J Clin Oncol 2006;29:371–375.
Oh SY, Kwon HC, Seo BG, Kin SH, Kim JS, Kim HJ, et al. A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer. Acta Oncol 2007;46:336–341.
Lee J, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol 2007;18:88–92.
Al-Batran S, Hartmann J, Probst S, Hofheinz R, Stoehlmacher J, Schmalenberg H, et al. A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving firstline chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). Proc Am Soc Clin Oncol 2006;2:4016.
Park I, Lee J, Ryu M, Chang H, Kim T, Sym S, et al. Phase I/II and pharmacokinetic study of combination chemotherapy with S-1 and oxaliplatin in patients with previously untreated metastatic or recurrent gastric cancer. Proc Am Soc Clin Oncol 2008;26:4557.
Boku N, Yamamoto S, Shirao K, Doi T, Sawaki W, Koizumi H, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Proc Am Soc Clin Oncol 2007;25:4513.
Narahara H, Koizumi W, Hara T, Takagane T, Akiya M, Takagi K, et al. Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (the SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. Proc Am Soc Clin Oncol 2007;25:4514.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kang, YK. Phase I/II studies of combination chemotherapy with S-1 and platinum in patients with previously untreated metastatic or recurrent gastric cancer. Gastric Cancer 12 (Suppl 1), 38–42 (2009). https://doi.org/10.1007/s10120-008-0472-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10120-008-0472-9